Event
Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch @ JPM 2026
Monday, January 12, 2026
Event Details
DateMonday, January 12, 2026
11:30 a.m. - 2:30 p.m. PT
For questions, please contact sfevents@sidley.com.
Join members of Sidley's Global Life Sciences team for a lunchtime CLE-accredited program during the JPM Healthcare Conference discussing the latest regulatory trends impacting the next wave of development-stage transactions.
Led by Meena Datta, global co-leader of Sidley's Healthcare practice; Torrey Cope, partner in Sidley's Food Drug and Medical Device (FDMD) practice; and Sally Wagner Partin, partner in Sidley's M&A practice, this session provides keen insights on the considerations driving recent biotech dealmaking. 1 hour CLE credit available.
Contacts
Offices
Related Resources
Capabilities
Suggested News & Insights
Sidley's 2026 San Diego Clinical Trial SeriesThursday, January 29, 2026 | Thursday, March 12, 2026 | Tuesday, April 21, 2026U.S. Clinical Trial Design & Execution RisksThursday, January 29, 2026Sidley Represents Simcere in €1 Billion Licensing and Collaboration Agreement With Boehringer IngelheimJanuary 29, 2025At the Table: Serving Up a Lively Discussion with the FDA, USDA, and HHSWednesday, January 28, 2026Delaware Supreme Court Makes Earnouts Less Risky For Buyers Earnout Decision Partially Reversed Because Buyer Did Not Have to Pursue an Alternative Regulatory PathwayJanuary 27, 2026Medical Products Market Access: Favorable Advisory Opinion Reaffirms Discounting FlexibilitiesJanuary 21, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory